- GSK to Buy Nuvalent for $10.6 Billion in Oncology Push WSJ
- Nuvalent shares surge 39% after UK’s GSK agrees to buy the cancer drugmaker for $10.6 billion CNBC
- GSK enters agreement to acquire Nuvalent, Inc. GSK
- GSK to buy US cancer biotech Nuvalent for $10.6bn Financial Times
- GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover Reuters
